Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
IAG Boss Walsh Disagrees With U.K. Quitting EU
28:01 - On the same day that Britain’s ruling Conservative Party outlined plans for a referendum on continued membership of the European Union, International Airlines Group chief executive Willie Walsh told Bloomberg he “strongly disagrees” with any move by the U.K. to quit. The comments make him one of the highest-profile business leaders to warn about the dangers of a breakaway.
  • Michael Kors Is a Busted, Yesterday Brand: Johnson
  • IAG Rules Out Increase on Aer Lingus Stake Offer
  • Arrests Made in FIFA Soccer Probe